The impact on survival of secondary risk–reducing strategies in carriers of the pathogenic variants of BRCA1 and BRCA2 with TN breast cancer after adjuvant chemotherapy is shown in Figures 4 and 5. This evidence concerns the gene BRCA2 and breast carcinoma.